There are many potential uses for such kits.
Link here to the relevant indications and read below for a quick overview.
LipidRescue® Therapy exerts several key physiological effects that together define the medical indications for which it can be used. These include binding lipid soluble drugs, increasing cardiac contractility and protecting heart cells from the injury that occurs after recovery from periods of poor coronary blood flow, ischemia-reperfusion injury (IRI). The clinical benefits of these effects include the rapid reversal of drug toxicity and improvement in heart function after acute, ischemic stress.
LipidRescue® Therapy is an effective antidote for toxicity caused by overdose of local anesthetics (LAST) and can also be used to treat a wide array of other (non-opiate) drug overdoses (NODO), including those caused by methamphetamine, cocaine, tricyclic antidepressants, anti-psychotics, beta-channel blockers and calcium-channel blockers.
LipidRescue® Therapy can reduce IRI and therefore theoretically improve cardiac function whenever blood flow has been restored to a heart where it had been interrupted. The adverse effects of IRI are seen very commonly after successful resuscitation from cardiac arrest as these patients often succumb a day or so later when the IRI severely impairs cardiac function. This is an example among many (e.g., after heart surgery, after heart transplant) where LipidRescue® Therapy could benefit patients with acute, life-threatening heart failure.
Toxicity. Data from animal and computer models of toxicity along with published clinical case reports and volunteer studies support the potential of LipidRescue® Therapy to reverse toxicity caused by overdose of lipid soluble drugs. In the clinical setting, LipidRescue® Therapy has been reported to rapidly reverse such toxicity, including both cardiovascular instability and alterations in central nervous system (CNS) function.
Cardiac. Data from a variety of animal and cell models and in several laboratories confirm that LipidRescue® Therapy can significantly improve cardiac function after a strong ischemic challenge where IRI has reduced cardiac contractility and performance.
LipidRescue® Therapy reverses LAST by a combination of three
key effects: a pharmacokinetic benefit (accelerated redistribution);
direct improvement of cardiac contractility; and protection from IRI.
The improved cardiac contractility is likely the result of combined activation of an insulin-like signaling effect and a potent
cell-protecting effect that diminishes IRI.
LipidRescue® Therapy for LAST has received approval for orphan drug designation by the FDA. ResQ Pharma held a preNDA meeting with FDA in Dec 2020 and plans to file an NDA for the LAST indication in 2021.
Combining its use in LAST and non-opiate drug overdoses (NODO), plus cardiac indications, LipidRescue® Therapy has the potential to benefit over 400,000 lives annually in the U.S. alone.